Pregled bibliografske jedinice broj: 1268423
Levels of neurofilament light chain protein in cerebrospinal fluid of spinal muscular atrophy patients treated with nusinersen
Levels of neurofilament light chain protein in cerebrospinal fluid of spinal muscular atrophy patients treated with nusinersen // NeuRi Abstract Book / Kužnik Pokorn, Jona ; Krmpotić, Rea (ur.).
Rijeka: Medicinski fakultet Sveučilišta u Rijeci, 2023. str. 41-41 (poster, domaća recenzija, sažetak, znanstveni)
CROSBI ID: 1268423 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Levels of neurofilament light chain protein in cerebrospinal fluid of spinal muscular atrophy patients treated with nusinersen
Autori
Banović, Maria ; Berečić, Ivana ; Babić, Marija ; Španić, Ena ; Vukić, Vana ; Vogrinc, Željka ; Sertić, Jadranka ; Barišić, Nina ; Šimić, Goran
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Izvornik
NeuRi Abstract Book
/ Kužnik Pokorn, Jona ; Krmpotić, Rea - Rijeka : Medicinski fakultet Sveučilišta u Rijeci, 2023, 41-41
Skup
12. Student Congress of Neuroscience – NeuRi 2023
Mjesto i datum
Rijeka, Hrvatska, 21.04.2023. - 23.04.2023
Vrsta sudjelovanja
Poster
Vrsta recenzije
Domaća recenzija
Ključne riječi
cerebrospinal fluid ; genetics ; motor functions ; neurofilament light chain ; nusinersen ; spinal muscular atrophy ; therapy
Sažetak
Introduction In this study, we aimed to determine whether the levels of neurofilament light chain (NFL) in cerebrospinal fluid (CSF) change after nusinersen treatment of patients with spinal muscular atrophy (SMA). In addition, we examined the relationship between NFL levels and genetic biomarkers of SMA (the number of copies of the NAIP gene and the number of copies of the 7th exon of the SMN2 gene). In addition, we examined whether there is a correlation between CSF NFL levels and motor function assessment scale scores in SMA patients, disease classification, and disease duration. Materials and Methods In this research, thirty patients with SMA were treated at the University Hospital Centre in Zagreb. Before administering nusinersen, CSF samples were obtained via lumbar puncture. SMA patients' motor functions were measured using the CHOP-INTEND (The Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders) scale and the HFMSE (The Hammersmith Functional Motor Scale Expanded) scale. The CHOP-INTEND scale was used to evaluate patients with SMA type 1, while the HFMSE scale was used to evaluate patients with SMA types 2 and 3. Using enzyme-linked immunosorbent assay analyses (ELISA, Enzyme-Linked Immunosorbent Assay), the protein concentrations in cerebrospinal fluid were determined. SPSS, version 19.0.1 (SPSS, Chicago, Illinois, United States) was used to analyze statistical data. Results CSF NFL levels moderately decreased in SMA patients after treatment with nusinersen, indicating that NFL protein is a moderately reliable biomarker for monitoring the response of SMA patients to nusinersen. NFL levels were negatively correlated with CHOP-INTEND scores and positively correlated with disease duration. There was no correlation between CSF NFL levels and genetic biomarkers of SMA and disease type. Discussion/Conclusion Since there was a negative correlation between NFL levels and the number of points on the CHOP-INTEND scale, NFL demonstrated statistical significance as a biomarker of favorable therapeutic response in SMA patients. Additionally, NFL levels were positively correlated with disease duration.
Izvorni jezik
Engleski
Znanstvena područja
Biologija, Temeljne medicinske znanosti, Kliničke medicinske znanosti, Kognitivna znanost (prirodne, tehničke, biomedicina i zdravstvo, društvene i humanističke znanosti), Biotehnologija u biomedicini (prirodno područje, biomedicina i zdravstvo, biotehničko područje)
POVEZANOST RADA
Ustanove:
Medicinski fakultet, Zagreb
Profili:
Nina Barišić
(autor)
Goran Šimić
(autor)
Jadranka Sertić
(autor)
Željka Vogrinc
(autor)
Ena Španić
(autor)